Early Lessons from Schistosomiasis Mass Drug Administration Programs

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2016 Mar 4

PMID 26937275

Citations 16

Authors

W Evan Secor

Affiliations

Soon will be listed here.

Abstract

Mass drug administration using praziquantel is the backbone of the current strategy for the control of schistosomiasis. As the theoretical plans have moved into practical application, certain challenges with this approach have surfaced, and it is likely that annual mass drug administration alone may not be sufficient to achieve program goals. However, mass drug administration is still the only available intervention that can be readily used in the wide variety of settings where schistosomiasis is endemic. The task then becomes how to improve this approach and identify what adjuncts to mass drug administration are effective, as programs move from morbidity control to elimination goals. Other aspects worthy of consideration include how best to employ new diagnostic tools to more easily identify where treatment is needed, and new formulations of praziquantel to extend the availability of treatment to all age groups. The aim of this review is to highlight both areas of challenge and of opportunity to improve the public health impact of schistosomiasis control programs.

Citing Articles

The Prevalence of and Its Impact on the Hematological Profile of Children Living in Northern Madagascar.

Wilczynska W, Kasprowicz D, Swietlik D, Korzeniewski K Pathogens. 2025; 14(2).

PMID: 40005547 PMC: 11858103. DOI: 10.3390/pathogens14020172.

Optimized strategy for schistosomiasis elimination: results from marginal benefit modeling.

Li Q, Zheng J, Jia T, Feng X, Lv C, Zhang L Parasit Vectors. 2023; 16(1):419.

PMID: 37968661 PMC: 10652544. DOI: 10.1186/s13071-023-06001-x.

Improving the Response of Health Systems to Female Genital Schistosomiasis in Endemic Countries through a Gender-Sensitive Human Rights-Based Framework.

Vlassoff C, Arogundade K, Patel K, Jacobson J, Gyapong M, Krentel A Diseases. 2022; 10(4).

PMID: 36547211 PMC: 9777435. DOI: 10.3390/diseases10040125.

Short-, Mid-, and Long-Term Epidemiological and Economic Effects of the World Bank Loan Project on Schistosomiasis Control in the People's Republic of China.

Li Q, Xu J, Li S, Utzinger J, McManus D, Zhou X Diseases. 2022; 10(4).

PMID: 36278583 PMC: 9624324. DOI: 10.3390/diseases10040084.

Estimating the financial impact of livestock schistosomiasis on traditional subsistence and transhumance farmers keeping cattle, sheep and goats in northern Senegal.

Adeyemo P, Leger E, Hollenberg E, Diouf N, Sene M, Webster J Parasit Vectors. 2022; 15(1):101.

PMID: 35317827 PMC: 8938966. DOI: 10.1186/s13071-021-05147-w.

References

Jothikumar N, Mull B, Brant S, Loker E, Collinson J, Evan Secor W . Real-time PCR and sequencing assays for rapid detection and identification of avian schistosomes in environmental samples. Appl Environ Microbiol. 2015; 81(12):4207-15. PMC: 4524150. DOI: 10.1128/AEM.00750-15. View

Tchuente L, Kuete Fouodo C, Ngassam R, Sumo L, Dongmo Noumedem C, Kenfack C . Evaluation of circulating cathodic antigen (CCA) urine-tests for diagnosis of Schistosoma mansoni infection in Cameroon. PLoS Negl Trop Dis. 2012; 6(7):e1758. PMC: 3409114. DOI: 10.1371/journal.pntd.0001758. View

Mwinzi P, Kittur N, Ochola E, Cooper P, Campbell Jr C, King C . Additional Evaluation of the Point-of-Contact Circulating Cathodic Antigen Assay for Schistosoma mansoni Infection. Front Public Health. 2015; 3:48. PMC: 4365547. DOI: 10.3389/fpubh.2015.00048. View

Won K, Abudho B, Blackstock A, Montgomery S, Kennedy E, Person B . Assessment of quality of life as a tool for measuring morbidity due to Schistosoma mansoni infection and the impact of treatment. Am J Trop Med Hyg. 2013; 90(2):322-8. PMC: 3919242. DOI: 10.4269/ajtmh.13-0361. View

Stothard J, Sousa-Figueiredo J, Betson M, Bustinduy A, Reinhard-Rupp J . Schistosomiasis in African infants and preschool children: let them now be treated!. Trends Parasitol. 2013; 29(4):197-205. PMC: 3878762. DOI: 10.1016/j.pt.2013.02.001. View

Njenga S, Mutungi F, Wamae C, Mwanje M, Njiru K, Bockarie M . Once a year school-based deworming with praziquantel and albendazole combination may not be adequate for control of urogenital schistosomiasis and hookworm infection in Matuga District, Kwale County, Kenya. Parasit Vectors. 2014; 7:74. PMC: 3936945. DOI: 10.1186/1756-3305-7-74. View

Worrell C, Bartoces M, Karanja D, Ochola E, Matete D, Mwinzi P . Cost analysis of tests for the detection of Schistosoma mansoni infection in children in western Kenya. Am J Trop Med Hyg. 2015; 92(6):1233-9. PMC: 4457354. DOI: 10.4269/ajtmh.14-0644. View

Lammie P, Moss D, Goodhew E, Hamlin K, Krolewiecki A, West S . Development of a new platform for neglected tropical disease surveillance. Int J Parasitol. 2012; 42(9):797-800. DOI: 10.1016/j.ijpara.2012.07.002. View

Lelo A, Mburu D, Magoma G, Mungai B, Kihara J, Mwangi I . No apparent reduction in schistosome burden or genetic diversity following four years of school-based mass drug administration in mwea, central kenya, a heavy transmission area. PLoS Negl Trop Dis. 2014; 8(10):e3221. PMC: 4191953. DOI: 10.1371/journal.pntd.0003221. View

10.

Knopp S, Corstjens P, Koukounari A, Cercamondi C, Ame S, Ali S . Sensitivity and Specificity of a Urine Circulating Anodic Antigen Test for the Diagnosis of Schistosoma haematobium in Low Endemic Settings. PLoS Negl Trop Dis. 2015; 9(5):e0003752. PMC: 4431728. DOI: 10.1371/journal.pntd.0003752. View

11.

Cioli D, Pica-Mattoccia L, Basso A, Guidi A . Schistosomiasis control: praziquantel forever?. Mol Biochem Parasitol. 2014; 195(1):23-9. DOI: 10.1016/j.molbiopara.2014.06.002. View

12.

Engels D, Chitsulo L, Montresor A, Savioli L . The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop. 2002; 82(2):139-46. PMC: 5633073. DOI: 10.1016/s0001-706x(02)00045-1. View

13.

Fenwick A . Praziquantel: do we need another antischistosoma treatment?. Future Med Chem. 2015; 7(6):677-80. DOI: 10.4155/fmc.15.16. View

14.

Ramaiah K, Ottesen E . Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis. 2014; 8(11):e3319. PMC: 4239120. DOI: 10.1371/journal.pntd.0003319. View

15.

Xu X, Zhang Y, Lin D, Zhang J, Xu J, Liu Y . Serodiagnosis of Schistosoma japonicum infection: genome-wide identification of a protein marker, and assessment of its diagnostic validity in a field study in China. Lancet Infect Dis. 2014; 14(6):489-97. DOI: 10.1016/S1473-3099(14)70067-2. View

16.

Lee E, Fairlie W . Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis. Future Med Chem. 2015; 7(6):707-11. DOI: 10.4155/fmc.14.164. View

17.

Evans D, Alphonsus K, Umaru J, Eigege A, Miri E, Mafuyai H . Status of Onchocerciasis transmission after more than a decade of mass drug administration for onchocerciasis and lymphatic filariasis elimination in central Nigeria: challenges in coordinating the stop MDA decision. PLoS Negl Trop Dis. 2014; 8(9):e3113. PMC: 4169246. DOI: 10.1371/journal.pntd.0003113. View

18.

Carvalho-Queiroz C, Nyakundi R, Ogongo P, Rikoi H, Egilmez N, Farah I . Protective Potential of Antioxidant Enzymes as Vaccines for Schistosomiasis in a Non-Human Primate Model. Front Immunol. 2015; 6:273. PMC: 4451692. DOI: 10.3389/fimmu.2015.00273. View

19.

Ross A, Olveda R, Chy D, Olveda D, Li Y, Harn D . Can mass drug administration lead to the sustainable control of schistosomiasis?. J Infect Dis. 2014; 211(2):283-9. DOI: 10.1093/infdis/jiu416. View

20.

. Schistosomiasis: number of people treated worldwide in 2013. Wkly Epidemiol Rec. 2015; 90(5):25-32. View